The Life Sciences team advised Q32 Bio on its $60 million Series B financing co-led by OrbiMed Advisors and Acorn Bioventures.
Q32 Bio is a clinical stage biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems to re-balance immunity in severe autoimmune and inflammatory diseases.
Proceeds from the Series B financing will support the advancement of ADX-914 through demonstration of proof-of-mechanism and propel the company’s groundbreaking tissue-targeted complement regulation platform. ADX-097 is the first fusion protein generated by Q32’s complement platform and is expected to enter Phase 1 in the fourth quarter of 2021. The financing also enables further refinement and expansion of both the company’s platform and pipeline.For more details, read the press release and articles in FierceBiotech, and Crunchbase News.